


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims

1. (Currently amended): A compound of formula (I)



in which:-

R^1 represents ~~pyrrolidin-1-yl, piperidin-1-yl or a group of formula~~




in which X represents ~~CH or N~~;

R^2 represents a hydrogen atom or a (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-4C)alkyl, fluoro(2-4C)alkanoyl, hydroxy(2-4C)alkyl or pyridyl group;

n represents 1, 2 or 3;

Z represents CH_2 , O or NR^5 , in which R^5 represents a hydrogen atom or a (1-4C)alkyl group, provided that when R^1 represents ~~pyrrolidin-1-yl, piperidin-1-yl or a group of formula~~



and Z represents O or NR^5 , then n represents 2 or 3;


R^3 represents:-

(i) phenyl which is unsubstituted or substituted by methylenedioxy or by a substituent selected from halogen, (1-4C)alkyl, hydroxy, (1-4C)alkoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl, carboxy, aminocarbonyl, amino, (2-4C)alkanoylamino, aminosulfonyl, (1-4C)alkylaminosulfonyl, nitro, phenyl, phenoxy, benzyloxy and pyridyl;

(ii) pyridyl, pyrimidyl or pyridazinyl, which is unsubstituted or substituted by a halogen atom;

- (iii) furyl, thienyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, each of which is unsubstituted or substituted by (1-4C)alkyl or amino;
- (iv) naphthyl, benzofuryl, benzothienyl, quinolyl or isoquinolyl;
- (v) (3-6C)cycloalkyl;
- (vi) piperidinyl or tetrahydropyranyl; or
- (vii) (1-4C)alkyl, which is unsubstituted or substituted by hydroxy, (1-4C)alkoxy, phenoxy, carboxy, aminocarbonyl, aminosulfonyl, (1-4C)alkylthio, phenylthio, pyridylthio, amino, (1-4C)alkylamino, di(1-4C)alkylamino, piperidin-1-yl, morpholino, trifluoromethyl, phenyl, imidazolyl, pyridyl, (3-6C)cycloalkyl, oxa(4-6C)cycloalkyl, or aza(4-6C)cycloalkyl (which may bear an N-(1-4C)alkyl substituent); and


R⁴ is selected from



in which

- X¹ represents a hydrogen atom, a halogen atom or an amino group;
- X² represents a hydrogen atom, a methyl group, a chlorine atom or a bromine atom;
- X³ represents a hydrogen atom, a methyl group or a halogen atom;
- X⁴ represents a chlorine atom, a methoxy group or a methyl group; and
- X⁵ represents a hydrogen atom, a halogen atom or a methyl group;
- or a pharmaceutically acceptable salt thereof.

2. (Currently Amended): A compound as claimed in Claim 1, in which R¹ represents a group of formula



in which X represents CH or N.

3. (Canceled)

4. (Previously presented): A compound as claimed in Claim 2, in which R^2 represents a (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-4C)alkyl, fluoro(2-4C)alkanoyl, hydroxy(2-4C)alkyl or pyridyl group.
5. (Previously presented): A compound as claimed in Claim 4, in which R^2 represents a methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, trifluoroacetyl, 2-hydroxyethyl or pyrid-4-yl group.
6. (Previously presented): A compound as claimed in Claim 5, in which R^2 represents an isopropyl, cyclopropyl, cyclopentyl or pyrid-4-yl group.
7. (Previously presented): A compound as claimed in Claim 1, in which n represents 1 or 2.
8. (Original): A compound as claimed in Claim 7, in which n represents 1.
9. (Previously presented): A compound as claimed in Claim 1, in which Z represents CH_2 .
10. (Previously presented): A compound as claimed in Claim 1, in which Z represents O.
11. (Previously presented): A compound as claimed in Claim 1, in which Z represents NR^5 .
12. (Original): A compound as claimed in Claim 11, in which R^5 is hydrogen.
13. (Previously presented): A compound as claimed in Claim 1, in which R^3 represents:-
- (i) phenyl, 2,3-methylenedioxyphenyl, 2-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 2-methylphenyl, 2-methoxyphenyl, 2-trifluoromethylphenyl, 2-difluoromethoxyphenyl, 4-carboxyphenyl or 4-aminocarbonylphenyl;
 - (ii) pyrid-2-yl or pyrid-4-yl;
 - (iii) fur-2-yl, fur-3-yl, thien-2-yl, thien-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-methylthiazol-4-yl or 2-aminothiazol-4-yl;
 - (iv) naphth-1-yl, naphth-2-yl, benzofuryl, benzothienyl, quinolin-4-yl or quinolin-8-yl;
 - (v) cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or

(vi) methyl, ethyl, propyl, isopropyl, butyl, 2-methylpropyl, hydroxymethyl, 1-hydroxyethyl, methoxymethyl, 1-methoxyethyl, methylthiomethyl, 2-methylthioethyl, prop-2-ylthiomethyl, N,N-dimethylaminomethyl, phenylthiomethyl, pyrid-2-ylthiomethyl, carboxymethyl, 2-carboxyethyl, aminocarbonylmethyl, 2-aminocarbonylethyl, morpholinomethyl, 2,2,2-trifluoroethyl, benzyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl, imidazol-1-ylmethyl, imidazol-4-ylmethyl, 3-methylimidazol-4-ylmethyl, cyclohexyl-4-ylmethyl, tetrahydropyran-4-ylmethyl, piperidin-1-ylmethyl or 1-methylpiperidin-4-ylmethyl.

14. (Original): A compound as claimed in Claim 13, in which R³ represents phenyl, 2-fluorophenyl or 2-chlorophenyl.

15. (Previously presented): A compound as claimed in Claim 14, in which R³ represents phenyl.

16. (Canceled)

17. (Canceled)


18. (Previously presented): A compound as claimed in Claim 1, in which R⁴ is 4-chlorophenyl, 4-methoxyphenyl, indol-6-yl, 3-methylindol-6-yl, 3-chloroindol-6-yl, 5-chloroindol-2-yl or 6-chlorobenzo[b]thiophen-2-yl.

19. (Previously presented): A compound as claimed in Claim 18, in which R⁴ is 4-methoxyphenyl, indol-6-yl or 5-chloroindol-2-yl.

20. (Previously presented): A pharmaceutical composition, which comprises a compound as claimed in Claim 1, together with a pharmaceutically acceptable diluent or carrier.

21. (Currently amended, withdrawn): A process for preparing a compound as claimed in Claim 1, which comprises

(a) reacting a compound of formula (II)



(II)

or a salt thereof, with a compound of formula (III)




(III)

or a reactive derivative thereof;

(b) for a compound of formula I in which R^2 represents a (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-4C)alkyl, fluoro(2-4C)alkanoyl or hydroxy(2-4C)alkyl, reacting a corresponding compound of formula (I) in which R^2 represents a hydrogen atom, or a salt thereof, with an alkylating or acylating agent;

(c) for a compound of formula (I) in which Z represents NH, deprotecting a compound of formula



(IV)


in which R^6 represents an amino protecting group; or

(d) for a compound of formula (I) in which R^2 represents a hydrogen atom, deprotecting a compound of formula (I) in which R^2 represents a protecting group;

followed, if a pharmaceutically acceptable salt is desired, by forming a pharmaceutically acceptable salt;


wherein, unless otherwise defined, R^1 , n, Z, R^3 and R^4 are as defined in Claim 1.

22. (Previously presented): A compound of formula (II)



or a salt thereof, in which R^1 , n , Z and R^3 are as defined in Claim 1.

23. (Currently amended): A compound of formula (IV)



or a salt thereof, in which R^6 represents an amino protecting group, and R^1 , n , R^3 and R^4 are as defined in Claim 1.

24. (Canceled)

25. (Canceled)

26. (Original): A method of treating a thrombotic disorder in a mammal requiring treatment, which comprises administering an effective amount of a compound as claimed in Claim 1.

27. (New): A compound as claimed in Claim 1 which is 3-chloro-N-[(R)-1-phenyl-2-(1-isopropylpiperidin-4-ylmethoxy)ethyl]-1H-indole-6-carboxamide, or a pharmaceutically acceptable salt thereof.